Genelux (NASDAQ:GNLX – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $30.00 price target on the stock.
Genelux Trading Down 12.5 %
Shares of GNLX traded down $0.49 during trading hours on Tuesday, reaching $3.41. 320,841 shares of the stock traded hands, compared to its average volume of 228,249. Genelux has a 52-week low of $1.60 and a 52-week high of $6.50. The company has a market cap of $117.60 million, a P/E ratio of -3.58 and a beta of -1.41. The company’s 50-day moving average price is $4.00 and its two-hundred day moving average price is $3.09.
Institutional Investors Weigh In On Genelux
Several large investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in Genelux during the 4th quarter valued at approximately $25,000. Apollon Wealth Management LLC grew its holdings in shares of Genelux by 20.4% in the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after purchasing an additional 2,857 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Genelux in the fourth quarter worth $41,000. Brown Brothers Harriman & Co. raised its stake in Genelux by 76.2% during the third quarter. Brown Brothers Harriman & Co. now owns 21,075 shares of the company’s stock valued at $50,000 after purchasing an additional 9,114 shares in the last quarter. Finally, D.A. Davidson & CO. bought a new position in Genelux during the fourth quarter valued at $51,000. 37.33% of the stock is owned by institutional investors.
Genelux Company Profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
Featured Stories
- Five stocks we like better than Genelux
- What is the Dogs of the Dow Strategy? Overview and Examples
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Why Invest in 5G? How to Invest in 5G Stocks
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
- Stock Splits, Do They Really Impact Investors?
- Oklo’s Stock Price Meltdown Is an Opportunity to Buy
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
